Focus on human microbiome to fight liver cirrhosis

22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.

Learn more

Annelotte Broekhoven appointed as new chair of the Early Career Scientists group

We congratulate Annelotte Broekhoven from Leiden University Medical Center for having been appointed as new chair of the MICROB-PREDICT Early Career Scientists group. She takes this important position over from her predecessor Romy Zwittink (also LUMC) who was the chair in the second year of the project, after Robert Schierwagen from Goethe University Frankfurt, who successfully filled this role in the first year. It will be Annelotte`s task to coordinate the training activities during the 3rd year which include amongst other things the organisation of the 2nd masterclass.

More news

MICROB-PREDICT Online Symposium connected to EASL School on Hepatology 2021

Symposium on 'Management of acute-on-chronic liver failure'
Course director: Prof. Jonel Trebicka
Date: Friday, September 3rd, 2021
Frankfurt, Germany

More events